Kornimate/medical-research-clean huggingface dataset:
effect on teeth and gum cleaning in patients with gum and kidney disease

Conditions: Renal Insufficiency Chronic; Chronic Periodontitis

Summary: the main aim and objective of this study was to evaluate the effects of non- surgical periodontal therapy on the subgingival microbiota and biochemical parameters in patients with chronic kidney disease and chronic periodontitis.

the study was designed as a non randomized prospective, interventional clinical trial. the sample size for the study was 40 individuals aged between 35-75 years, equally divided into two groups. group i--- patients with chronic kidney disease and chronic periodontitis (test) group ii--- patients with chronic periodontitis only (controls) at baseline both the groups were analyzed for clinical, microbiological and also biochemical parameters and underwent non-surgical periodontal treatment (i.e. scaling and root planning). all parameters were reassessed again after 3 months. a total of 20 patients attending the outpatient wing of hyderabad kidney centre , malakpet,hyderabad who were diagnosed clinically with chronic kidney disease and willing to participate in the study were included in the study. another 20 patients attending the outpatient wing of department of periodontics, panineeya mahavidyalaya institute of dental sciences \& hospital, hyderabad, diagnosed with chronic periodontitis and willing to participate in the study were taken. biochemical parameters considered included -serum creatin \& urinary albumin: creatin ratio. microbiological assay was done by polymerase chain reaction test (pcr) i.e., pooled plaque samples were taken from both predialysis as well as chronic periodontitis patients.

Eligibility criteria:
inclusion criteria: * a total of 20 patients diagnosed with chronic kidney disease, (having abnormal glomerular filtration rate(gfr) and serum creatinine levels.) and chronic periodontitis (with at least 15 teeth remaining, and with the presence of ≥4 sites in 3 different teeth having clinical attachment loss (cal) of ≥ 4mm and bleeding on probing). (group i) * 20 patients diagnosed with chronic periodontitis only. (groupii) exclusion criteria: * patients with hiv infection, pregnancy, lupus erythematosus, rheumatoid arthritis, any systemic disorder, periodontal therapy in the preceding 6 months, or on any course of antibiotic prophylaxis for periodontal procedures were excluded from the study
comparative effects of closed kinetic chain exercises and mobilization exercises in elderly females with nff

Conditions: Neck of Femur Fracture

Summary: this study investigates the additional benefits of mobilization exercises and closed kinetic chain exercises (ckce) in elderly individuals with post-operative neck of femur fracture. the researcher employs a randomized controlled trial which will involve 49 participants aged above 65 years with post-operative neck of femur fracture.

participants are divided into two groups: one receiving mobilization exercises, and the other receiving closed kinetic chain exercises. outcomes are assessed over a 6 week period, focusing on pain intensity, range of motion, risk of fall by goniometer, visual analogue scale (vas) and dynamic gait index (dgi) scores. data will be analyzed using spss-23. the study will conclude whether ckce or mobilization exercises offer a significant benefit in pain reduction, prevent risk of falls and range of motion.

Eligibility criteria:
inclusion criteria: * diagnosed by orthopedic surgeon with neck of femur fracture by x ray findings * patients undergone surgical treatment for neck of femur fracture within one year. * patients administer in groups after 12 weeks of post-operative period * x-ray reexamination with no fracture or dislocation before treatment * ability to walk normally or with crutches * patients walk without any assistance before injury * un-displaced neck of femur fracture according to garden classification * operated on using internal fixation * only females were included * aged 65 years or older exclusion criteria: * bilateral hip fracture * bedridden patient before fracture * patient who have undergone any previous surgery of lower limb * neurological condition
ldd in treatment of femoropopliteal isr

Conditions: Peripheral Artery Disease; In-stent Restenosis

Summary: this study will evaluate the effectiveness and safety of local drug delivery using tapas balloon catheter system in the treatment of femoropopliteal in-stent restenosis. patients with femoropopliteal in-stent restenosis will randomly receive balloon dilation or balloon dilation plus local drug delivery using balloon catheter system. their clinical outcomes (e.g. 12-month late lumen loss or late lumen loss at secondary intervention within 12 months, 6-month and 1-year patency rate of target vessel) in 1 year after the treatment will be compared.

femoropopliteal occlusive disease is a common type of peripheral arterial disease. endovascular treatment has been the first-line treatment of femoropopliteal occlusive disease. however, the in-stent re-stenosis has been a major limitation of well long-term patency after stent implantation. the chronic inflammation induced by stenting could be a main reason of restenosis. then the concept "leave nothing behind" is proposed, and some novel treatment methods and devices are developed. here, the investigators propose the hypothesis that using local drug delivery with tapas balloon system can relieve the inflammation induced by the stent implantation and balloon dilation. therefore, 40 patients of femoropopliteal in-stent restenosis will be randomly allocated into the group "balloon dilation+local drug delivery with balloon system" or "balloon dilation only". the 1-year patency rate,12-month late lumen loss, incidence of complications, imaging parameters will be compared between two groups.

Eligibility criteria:
inclusion criteria: * have signed the informed consent * age of 18-80 years old * femoropopliteal artery disease (rutherford 2-4) * femoropopliteal in-stent restenosis (≥70%) * length of lesion ≤ 20cm * at least one infrapopliteal run-off vessel exclusion criteria: * serum cr \> 150 umol/l * patients with acute thrombosis * stent fracture within femoropopliteal artery * allergic to aspirin, heparin, clopidogrel, paclitaxel, contrast medium * already recruited into other clinical trials that could influence the outcome of this study * pregnancy and lactation * relatively easy bleeding * malignancy or irreversible organ failure

Keywords: femoropopliteal occlusive disease local drug delivery endovascular treatment
gore® viabahn® endoprosthesis post-marketing surveillance study

Conditions: Vascular Stent-Graft Stenosis

Summary: this study will confirm the efficacy and safety in the clinical setting after the launch of the gore® viabahn® stent graft (hereafter referred to as "viabahn") for the treatment of patients with stenosis or occlusion at the venous anastomosis of synthetic arteriovenous access graft.


Eligibility criteria:
inclusion criteria: * participants who developed stenosis or occlusion at the venous anastomosis of synthetic arteriovenous access graft * participants who was used to repair vascular access circuits for purposes other than treatment of stenosis or occlusion at the venous anastomosis of synthetic arteriovenous access graft
adult tic disorders registry

Conditions: Tic Disorders

Summary: the purpose of this study is to develop the adult tic disorders registry in order to characterize the relationship between tic severity and tic-related impairment in women compared to men with tic disorders.


Eligibility criteria:
inclusion criteria : 1. age \>18 years 2. patients with tic disorders 3. given the non-opposition non inclusion criteria 1. no affiliation to a french health social insurance 2. significant congenital disorders that may affect understanding of assessments 3. patients under guardianship or curatorship
regenerative potential of advanced platelet rich fibrin and bioactive glass (perioglas®).

Conditions: Chronic Periodontitis; Bone Loss; Intrabony Periodontal Defect

Summary: the aim of this study is to evaluate and compare the regenerative potential of advanced platelet rich fibrin (a-prf) and bioactive glass (perioglas®) bone graft in the treatment of intrabony defects in chronic periodontitis patients.

45 sites with vertical intrabony alveolar defects will be selected. these defect sites will be allocated randomly into 3 groups as group i, group ii and group iii. * group i will be treated with open flap debridement and filled with a-prf * group ii will be treated with open flap debridement and filled with bioactive glass (perioglas®) * group iii will be treated with open flap debridement and filled bioactive glass (perioglas®) and a-prf.

Eligibility criteria:
inclusion criteria: * age: 25 to 55 years. * gender: both males and females will be included in the study. * co-operative and motivated patients committed to oral hygiene. * patients exhibiting intrabony defects. exclusion criteria: * patients with contraindication to periodontal surgery \& local anesthesia. * any systemic disease affecting the bone density and outcome of periodontal therapy. * smokers, alcoholics, and patients with other adverse habits. * pregnant, nursing and menopausal women. * any known allergy/ hypersensitivity to any product used in this study. * patients on long-term systemic therapy (antibiotics, anti-inflammatory bisphosphonates, hormonal replacement therapy and any other), taking any drug known to have periodontal implications that may interfere with wound healing. * patients taking any anti-platelet and anticoagulant medication. * patients who have undergone periodontal treatment within a period of past 1 year.

Keywords: intrabony periodontal defect regeneration platelet rich fibrin bioactive glass
eating mindfully to prevent weight regain

Conditions: Weight Loss; Weight Gain; Eating Behavior; Obesity; Bariatric Surgery Candidate

Summary: the overall objective of this study is to evaluate the efficacy of a mindfulness-based intervention to prevent weight regain in weight-reduced adults.

specific aim 1: determine the effect of more on weight loss maintenance. hypothesis: more will result in less weight regain compared to con after the 8-week intervention, and benefits will be sustained after 6-month of follow-up. specific aim 2: determine the effect of more on reward-related behavioral processes (e.g., food cravings) and ad libitum energy intake. hypothesis: more group will demonstrate changes in eating behaviors and energy intake associated with preventing weight regain compared to con immediately after more and after 6-months of follow-up.

Eligibility criteria:
inclusion criteria: * age 18-65 * bariatric surgery patients: 12-18 months post-operation. * medical weight loss patients: patients of the bariatric weight loss clinic, weight loss of 7% body mass via intentional weight loss within past 6 months; bmi \>25 kg/m2 prior to intentional weight loss; stable for 3 months on medications. * lifestyle weight loss: weight loss of 7% body mass via intentional weight loss within past 6 months; bmi \>25 kg/m2 prior to intentional weight loss. exclusion criteria: * uncontrolled cardiovascular, metabolic, renal, or pulmonary disease; cancer treatment in past 5 years; untreated thyroid disease or other medical condition affecting weight or energy metabolism; severe food allergies; women who are pregnant, lactating, or planning pregnancy during participation in the trial; active psychiatric issues * additional criteria specific to patients with history of bariatric surgery: \ 5% of body mass postoperation; history of admittance to rehabilitation facility; history of post-op complications that require recent inpatient management; patients who were required to stay in the hospital \>1 week post-op; revision surgery patients; heart failure patients.

Keywords: appetite regulation weight regain prevention weight loss maintenance mindfulness mindfulness orientated recovery enhancement
the effects of mindsets on the brain's response to food cues

Conditions: Obesity

Summary: previous studies have shown that obese individuals exhibit greater reward-related brain activity in response to food cues than lean individuals and our group has shown that successful weight loss maintainers who were previously obese and now maintain a healthy weight have increased control-related activity when viewing food cues. these findings suggest key roles for both reward-related brain areas and inhibitory control regions in eating behavior. however, no studies to date have examined (a) whether the response to food cues (i.e., cue-reactivity) can be changed in obese individuals, (b) which strategies are most effective at altering brain response to food cues, or (c) the neural mechanisms that support such change. given the omnipresent environmental cues to eat and the association between heightened reward-responsivity and obesity, it is critical to investigate ways to potentially alter food cue-reactivity in the obese. the most widely employed approach for behavioral weight loss treatment is cognitive behavioral therapy (cbt), which incorporates strategies to control and change cognitions (e.g., avoid desire to eat tempting foods by focusing on something else). this approach is sometimes described as "change- focused" because modifying negative thoughts is assumed to thereby change associated maladaptive emotions and behaviors. alternatively, emerging evidence suggests acceptance and commitment therapy (act), which teaches participants to recognize and accept their cravings as feelings that need not be acted upon, may also be effective in treating obesity. a third strategy often employed in smoking cessation and substance abuse treatment is to focus on the long-term consequences of behaviors, however this form of treatment is not typically used in behavioral weight loss therapy. thus although each approach is potentially effective, these treatment approaches differ greatly in the cognitive strategies they employ. the primary aim of the proposed research is to compare a cognitive strategy used in cbt ('change'), a cognitive strategy emphasized in act ('accept'), and a cognitive strategy used in smoking cessation ('later') relative to a control condition ('now'), in their effectiveness in altering reward and inhibitory control responses to food cues among obese individuals.


Eligibility criteria:
inclusion criteria: * mri compatibility * 25-55 yrs old * 25-40 bmi * weight stable * right handed exclusion criteria: * mri incompatibility * left handed

Keywords: fmri cognitive strategies obesity weight loss mindsets
antipsychotics and gene expression in soft tissues

Conditions: Schizophrenia; Diabetes

Summary: schizophrenia is a severe chronic and disabling mental disorder and is associated with a significant reduction in life expectancy. atypical antipsychotic treatment compliance may be jeopardized because of drug induced weight gain and abnormalities in carbohydrate and lipid metabolism. aim: to gain data on drug related effects on gene expression and regulation with special regard to glucose metabolism.


Eligibility criteria:
inclusion criteria: * male. * healthy, defined as absence of relevant diseases. * caucasian. * aged 18-45 years. * body-mass-index (bmi): 18-25 kg/m2. * signed informed consent. * no signs of impaired glucose tolerance as evaluated by oral glucose tolerance test (ogtt) before study inclusion during screening, normal total cholesterol, high density lipoprotein (hdl), low density lipoprotein (ldl), triglycerides, normal function of the thyroid. no personal or family history (parents and siblings) of diabetes or other metabolic and relevant diseases as defined by the investigator. * no indication for psychiatric diseases assessed by structured clinical interview (mini-international neuropsychiatric interview (mini)). exclusion criteria: * personal or family history (parents and siblings) of diabetes or other metabolic diseases, relevant diseases as defined by the investigator. * history of hypertension, blood pressure \> 140/90 at screening, cardiovascular disease. * body mass index out of the range of \ 25 kg/m. * human immunodeficiency virus (hiv) or hepatitis b/c positive virology. * allergy or hypersensitivity against olanzapine/ziprasidone or another excipient. * contraindications against the use of the drug according to the summary of product characteristics (smpc). * any drug intake 2 weeks prior to first study day. * history of excessive bleeding tendency/hemophilia. * presence of relevant illness within the last 3 weeks. * currently enrolled into an other clinical study with investigational medicinal products (imps). * last study participation less than 4 weeks. * suspected non-compliance with study instructions and life-style requirements. * history of alcohol or drug abuse. * blood/plasma donation within 4 weeks prior to study day. * previous exposure to antipsychotic drugs. * nicotine consumption at time of enrolment (at least 3 months of non-smoking required).

Keywords: healthy volunteers antipsychotics gene expression
efficacy of fosmidomycin-clindamycin for treating malaria in gabonese children

Conditions: Malaria

Summary: there is a necessity for the development of new malaria drugs. some antibiotics are also effective against malaria parasites. fosmidomycin is an antibiotic that has been shown to be effective against malaria, although it cannot achieve a total cure in all patients. previous small studies have shown that in combination with clindamycin, an commonly used antibiotic, it is highly effective and safe when given for three days, leading to a total cure in most patients. the current study will evaluate its efficacy in a larger population in gabon, and compare its effect with the generally used drug, sulfadoxine-pyrimethamine.

fosmidomycin-clindamycin (30 mg/kg and 10 mg/kg) given twice daily for three days is an effective and safe combination of antibiotics which demonstrated good activity against malaria parasite in previous phase ii studies in african children. in this phase iii trial, the efficacy and safety of the combination will be evaluated in african children with uncomplicated p. falciparum malaria. a single dose of sulfadoxine-pyrimethamine, the standard antimalarial in gabon, is used as comparator.

Eligibility criteria:
inclusion criteria: * uncomplicated p. falciparum malaria * p. falciparum asexual parasitaemia between 1,000/µl and 100,000/µl * body weight between 10 - 65 kg * ability to tolerate oral therapy * informed consent, oral assent of the child, if possible * residence in study area exclusion criteria: * adequate anti-malarial treatment within the previous 7 days * antibiotic treatment for the current infection * previous participation in this clinical trial * haemoglobin \< 7 g/dl * haematocrit \< 23 % * leucocyte count \> 15,000 /µl * mixed plasmodial infection * severe malaria (as defined by who) * any other severe underlying disease (cardiac, renal, hepatic diseases, malnutrition, known hiv infection) * concomitant disease masking assessment of response * history of allergy or intolerance against trial medication

Keywords: malaria fosmidomycin clindamycin chemotherapy gabon
a trial of multiple-doses of aripiprazole in adults with schizophrenia or bipolar 1 disorder

Conditions: Schizophrenia; Bipolar I Disorder

Summary: the purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following the final administration of aripiprazole into the gluteal muscle site, and to establish the similarity of aripiprazole exposure over the dosing interval following the administration of aripiprazole into the gluteal muscle site in adult participants with schizophrenia or bipolar i disorder.


Eligibility criteria:
inclusion criteria: * a current diagnosis of schizophrenia or bipolar i disorder, as defined by diagnostic and statistical manual of mental disorders, fifth edition (dsm-5) criteria. * body mass index of 18 to 35 kilograms per meter square (kg/m\^2). * on a stable dose of an atypical oral antipsychotic medication for at least 2 months prior to screening. exclusion criteria: * participants who have: * met dsm-5 criteria for substance use disorder within the past 180 days. * a positive drug screen for drugs of abuse * use of any psychotropic medications other than their current non-aripiprazole antipsychotic or mood stabilizer(s) medication; or participants who use more than one antipsychotic or mood stabilizer(s) medication at screening. * females who are pregnant, breast-feeding, lactating, and/or have a positive pregnancy test result prior to receiving investigational medicinal product (imp). a negative serum pregnancy test must be confirmed prior to the first dose of imp for all female participants. * any major surgery within 30 days prior to enrollment or scheduled/elective surgery during the trial. * evidence of organ dysfunction or any clinically significant deviation from normal in the physical, electrocardiographic, or clinical laboratory examinations. * participants currently in an acute relapse of schizophrenia. * participants with a current dsm-5 diagnosis other than schizophrenia or bipolar i disorder, including schizoaffective disorder, major depressive disorder, delirium, dementia, amnestic, or other cognitive disorders. also, participants with borderline, paranoid, histrionic, or antisocial personality disorder. * participants with a history of neuroleptic malignant syndrome or clinically significant tardive dyskinesia. * history of any significant drug allergy or known or suspected hypersensitivity, in particular to aripiprazole or other quinolinones. * history of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis b surface antigen (hbsag) or hepatitis c antibodies (anti-hcv), and/or human immunodeficiency virus (hiv) antibodies. * participants deemed intolerant of receiving injections. * participants who have had electroconvulsive therapy within 2 months of administration of imp.

Keywords: aripiprazole aripiprazole intramuscular depot gluteal muscle long acting injection